Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder

JAMA Neurology

Volumn 71, Issue 11, 2014, Pages 1372-1378

  Huh, So Young ^a   Kim, Su Hyun ^b   Hyun, Jae Won ^b   Joung, Ae Ran ^b   Park, Min Su ^c   Kim, Byung Jo ^d   Kim, Ho Jin ^b  

^a Kosin University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Yeungnam University College of Medicine   (South Korea)

^d Korea University Ansan Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; MYCOPHENOLIC ACID;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; FOLLOW UP; HAIR LOSS; HERPES ZOSTER; HUMAN; KOREA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYELOOPTIC NEUROPATHY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RASH; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISABILITY; MIDDLE AGED; MULTICENTER STUDY; NEUROMYELITIS OPTICA; RECURRENT DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEUROMYELITIS OPTICA; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919343736     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.2057     Document Type: Article

References (30)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-1114.
2. Kim W, Kim SH, Kim HJ. New insights into neuromyelitis optica. J Clin Neurol. 2011;7(3):115-127.
3. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51(4):1219-1220.
4. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66(9):1128-1133.
5. Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324-330.
6. Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013;84 (8):918-921.
7. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270-1272.
8. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443-1448.
9. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310-1315.
10. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17(10):1225-1230.
11. Kim SH, KimW, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68(11):1412-1420.
12. Ip VH, Lau AY, Au LW, et al. Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci. 2013;324(1-2):38-39.
13. Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler. 2012;18(7):1022-1026.
14. Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110-1117.
15. Yang CS, Yang L, Li T, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology. 2013;81(8):710-713.
16. Kim SH, KimW, ParkMS, Sohn EH, Li XF, Kim HJ. Efficacy and safety ofmitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol. 2011;68(4):473-479.
17. Cabre P, Olindo S, Marignier R, Jeannin S, Merle H, Smadja D; Aegis of French National Observatory of Multiple Sclerosis. Efficacy ofmitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry. 2013;84(5):511-516.
18. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77 (7):659-666.
19. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, Amorin de Souza N, Gabbai AA. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol. 2010;67(9):1131-1136.
20. Cohen BA,Mikol DD.Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology. 2004;63(12)(suppl 6):S28-S32.
21. Marriott JJ,Miyasaki JM, Gronseth G, O'Connor PW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010; 74(18):1463-1470.
22. Ellis R, Boggild M. Therapy-related acute leukaemia with mitoxantrone: what is the risk and canwe minimise it? Mult Scler. 2009;15(4):505-508.
23. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF,Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66(10):1485-1489.
24. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ,Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9): 805-815.
25. Elsone L, Kitley J, Luppe S, et al. Long term efficacy, adherence and reasons for discontinuation in 103 cases of neuromyelitis optica treated with azathioprine: a multicentre study from the United Kingdom. In: ECTRIMS 2013 c/o Congrex Switzerland Ltd, ed. European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Copenhagen, Denmark: University of Oxford; 2013. Paper 159.
26. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2-3):85-118.
27. Eickenberg S,Mickholz E, Jung E, Nofer JR, Pavenstadt HJ, Jacobi AM. Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus. Arthritis Res Ther. 2012;14(3):R110. doi:10.1186/ar3835.
28. Chan TM, Tse KC, Tang CS, Mok MY, Li FK; Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J AmSoc Nephrol. 2005;16(4): 1076-1084.
29. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated withmycophenolate mofetil. Am J Transplant. 2005;5(12):2954-2960.
30. Laskari K, Mavragani CP, Tzioufas AG, Moutsopoulos HM. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. Arthritis Res Ther. 2010;12(6):R208. doi:10.1186/ar3184.